ACE2 and Angiotensin-(1-7) in Hypertensive Renal Disease.
- Author:
Ju Young MOON
1
Author Information
- Publication Type:Review
- Keywords: ACE; ACE2; angiotensin II; angiotensin-(1-7)
- MeSH: Angiotensin I; Angiotensin II; Hypertension; Kidney; Kidney Diseases; Nitric Oxide; Peptide Fragments; Peptidyl-Dipeptidase A; Rats, Inbred SHR; Renal Circulation; Sodium; Vasodilation; Water; Axis, Cervical Vertebra
- From:Electrolytes & Blood Pressure 2011;9(2):41-44
- CountryRepublic of Korea
- Language:English
- Abstract: The recently discovered angiotensin-converting enzyme-related carboxypeptidase 2 (ACE2)-[Angiotensin-(1-7)(Ang-(1-7)]-Mas receptor axis has an opposing function to that of the ACE-Angiotensin II (Ang II)-Angiotensin type 1 (AT1) receptor axis. Ang-(1-7) is present in the kidneys at concentrations comparable to those of Ang II and is associated with vasodilation, modulation of sodium and water transport, and stimulation of nitric oxide (NO) synthase. Ang-(1-7) also acts as a physiological antagonist of Ang II by counterbalancing the Ang II-mediated intracellular signaling pathway. In a hypertensive model, increased ACE and decreased ACE2 along with a higher ACE/ACE2 ratio in hypertensive kidneys appeared to favor Ang II generation, leading to hypertensive renal damage. In addition, the administration of a selective Ang-(1-7) receptor blocker or an ACE2 inhibitor was associated with worsening of hypertension and renal function. Ang-(1-7)-mediated increases in renal blood flow were abolished by blockade of the Mas receptor and by inhibition of prostaglandin release and NO in spontaneously hypertensive rats and in Wistar-Kyoto controls. Further research on the function of the ACE2-Ang-(1-7)-Mas receptor axis could lead to a novel target for inhibiting kidney disease progression.
